DE60232077D1 - Verwendung mindestens einer glycoinhibitor-substanz gegen infektionskrankheiten - Google Patents

Verwendung mindestens einer glycoinhibitor-substanz gegen infektionskrankheiten

Info

Publication number
DE60232077D1
DE60232077D1 DE60232077T DE60232077T DE60232077D1 DE 60232077 D1 DE60232077 D1 DE 60232077D1 DE 60232077 T DE60232077 T DE 60232077T DE 60232077 T DE60232077 T DE 60232077T DE 60232077 D1 DE60232077 D1 DE 60232077D1
Authority
DE
Germany
Prior art keywords
glycoinhibitor
against infection
infection diseases
substance against
neutral glycan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60232077T
Other languages
English (en)
Inventor
Jari Natunen
Halina Miller-Podraza
Susann Teneberg
Jonas Angstroem
Karl-Anders Karlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glykos Finland Ltd
Original Assignee
Glykos Finland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20011403A external-priority patent/FI20011403A/fi
Priority claimed from FI20011402A external-priority patent/FI20011402A/fi
Application filed by Glykos Finland Ltd filed Critical Glykos Finland Ltd
Application granted granted Critical
Publication of DE60232077D1 publication Critical patent/DE60232077D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE60232077T 2001-06-29 2002-06-28 Verwendung mindestens einer glycoinhibitor-substanz gegen infektionskrankheiten Expired - Fee Related DE60232077D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20011403A FI20011403A (fi) 2001-06-29 2001-06-29 Menetelmä ja koostumukset vatsan sairauksien hoitoon
FI20011402A FI20011402A (fi) 2001-06-29 2001-06-29 Lääkkeet ja hoitotavat patogeenejä vastaan
PCT/FI2002/000574 WO2003002127A1 (en) 2001-06-29 2002-06-28 Use of at least one glycoinhibitor substance

Publications (1)

Publication Number Publication Date
DE60232077D1 true DE60232077D1 (de) 2009-06-04

Family

ID=26161191

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60232077T Expired - Fee Related DE60232077D1 (de) 2001-06-29 2002-06-28 Verwendung mindestens einer glycoinhibitor-substanz gegen infektionskrankheiten

Country Status (7)

Country Link
US (1) US20040176320A1 (de)
EP (1) EP1411952B1 (de)
JP (1) JP2005504017A (de)
AT (1) ATE429233T1 (de)
AU (1) AU2002352531A1 (de)
DE (1) DE60232077D1 (de)
WO (1) WO2003002127A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411962B1 (de) 2001-03-15 2011-01-19 Neogenix Oncology, Inc. Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE60327211D1 (de) * 2002-06-28 2009-05-28 Glykos Finland Oy Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall
CA2542448A1 (en) † 2003-10-13 2005-05-06 Nestec S.A. Moderating the effect of endotoxins
US20070074300A1 (en) * 2005-09-28 2007-03-29 Suleiman Igdoura Sialidase inhibitors for the treatment of cardiovascular disease
JP5035787B2 (ja) * 2005-10-04 2012-09-26 焼津水産化学工業株式会社 α−１、４結合型Ｎ−アセチルグルコサミン含有Ｏ−グリカン型糖鎖の分泌促進剤並びにこれを含有するヘリコバクターピロリ菌を原因とする病態の治療予防剤
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
JP5014018B2 (ja) * 2006-10-18 2012-08-29 旭化成ケミカルズ株式会社 ピロリ菌の抑制剤または静菌剤
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
EP2060257A1 (de) * 2007-11-08 2009-05-20 Nestec S.A. Vorbeugung und Behandlung von Sekundärinfektionen nach Virusinfektion
SG188887A1 (en) 2008-03-14 2013-04-30 Nestec Sa Synbiotic mixture
WO2009152089A2 (en) * 2008-06-09 2009-12-17 Temple-Inland Prebiotic composition and methods of making and using the same
GB0817908D0 (en) 2008-10-01 2008-11-05 Univ Ghent Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
US9678005B1 (en) * 2008-12-03 2017-06-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Devices and methods for detection of microorganisms
US8785402B2 (en) * 2009-07-31 2014-07-22 Academia Sinica Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions
GB2485953B (en) 2009-08-27 2014-07-23 Temple Inland Methods of making and using a ruminant gas reduction composition
WO2011072051A2 (en) 2009-12-08 2011-06-16 Temple-Inland Nutritional composition and methods of making and using same
JP6170675B2 (ja) * 2010-01-28 2017-07-26 ラプトール ファーマシューティカルズ インコーポレイテッド 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法
CN102811720A (zh) 2010-03-25 2012-12-05 白色生物技术公司 亚氨基环醇类作为上皮细胞细菌粘附抑制剂的用途
WO2015123433A2 (en) * 2014-02-12 2015-08-20 Goddard Labs, Inc. Rapid detection of human pathogens in plant material or water
PL3116887T3 (pl) 2014-03-13 2021-09-06 Universität Basel Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną
KR101613964B1 (ko) 2014-05-20 2016-04-21 농업회사법인 주식회사 생명의나무 글라이코매크로펩타이드 효소분해물을 유효성분으로 하는 헬리코박터 파이로리 감염 예방 또는 치료용 조성물
JP6849667B2 (ja) 2015-09-16 2021-03-24 ウニヴェルズィテート バーゼル スフィンゴ糖脂質の糖鎖エピトープに対する抗体に結合する炭水化物リガンド
BR112018012821B1 (pt) * 2015-12-22 2022-02-22 Universidad Nacional De Colombia Glicoinibidor que inibe a adesão da bactéria streptococcus que afeta o trato digestivo do peixe
EP3184536A1 (de) * 2015-12-22 2017-06-28 Westfälische Wilhelms-Universität Münster Oligosaccharidzusammensetzung zum binden an lectine
CA3102152A1 (en) * 2018-06-19 2019-12-26 Glykos Biomedical Oy Conjugate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
HU9502497D0 (en) * 1993-02-26 1995-10-30 Normark Use of oligosaccharide glycosides as inhibitors of bacterial adherence
DE4408248A1 (de) * 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
US5665561A (en) * 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US5641760A (en) * 1994-06-17 1997-06-24 Pence, Inc. Method of treating candida infection
EP0918526A1 (de) * 1996-05-03 1999-06-02 Neose Technologies, Inc. Bismuthsalz von sialyloligosaccharid und verfahren zur behandlung von magen- und duodenalgeschwürer damit
SE9901007D0 (sv) * 1999-03-19 1999-03-19 Thomas Boren Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
US6664235B1 (en) * 1999-08-20 2003-12-16 Riken Medicaments comprising sialic acid derivatives as active ingredients
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof

Also Published As

Publication number Publication date
EP1411952A1 (de) 2004-04-28
JP2005504017A (ja) 2005-02-10
US20040176320A1 (en) 2004-09-09
EP1411952B1 (de) 2009-04-22
ATE429233T1 (de) 2009-05-15
WO2003002127A1 (en) 2003-01-09
AU2002352531A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
DE60232077D1 (de) Verwendung mindestens einer glycoinhibitor-substanz gegen infektionskrankheiten
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
PT1333887E (pt) Metodo de tratamento de desordens musculares
BR0311326A (pt) Imidazol-2-tionas de 4-(substituìda cicloalquilmetila), imidazol-2-tionas de 4-(substituìda cicloalquenilmetila), imidazol-2-onas de 4-(substituìda cicloalquilmetila) e imidazol-2-onas de 4-(substituìda cicloalquenilmetil) e compostos relacionados
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
DK0841949T3 (da) Anvendelse af saccharid-konjugater
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
DE60204722D1 (de) Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten
BR0206568A (pt) Novo método e composições para o tratamento local de doença de meniere, de zumbido no ouvido e/ou de perda de audição
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
PT998287E (pt) Utilizacao de levobupivacaina
BRPI0408295A (pt) uso de um composto
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
DK1368019T4 (da) Esmololformulering
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
DK1305037T3 (da) Smertestillende medikament
BR9916190A (pt) Emprego de inibidores do canal kqt1 para a preparação de um medicamento para o tratamento de doenças, que são provocadas por helmintos e ectoparasitas
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
SE0004101D0 (sv) New use
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee